NORTHSTAR ASSET MANAGEMENT Co Sells 1,093 Shares of Thermo Fisher Scientific Inc. $TMO

NORTHSTAR ASSET MANAGEMENT Co lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,288 shares of the medical research company’s stock after selling 1,093 shares during the quarter. Thermo Fisher Scientific accounts for about 1.9% of NORTHSTAR ASSET MANAGEMENT Co’s investment portfolio, making the stock its 11th largest position. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Thermo Fisher Scientific were worth $8,226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Lafayette Investments Inc. grew its stake in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock worth $376,000 after buying an additional 22 shares during the last quarter. Root Financial Partners LLC boosted its stake in Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 24 shares during the last quarter. Rossmore Private Capital lifted its holdings in shares of Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 24 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its holdings in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after buying an additional 24 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,666 shares of company stock worth $13,990,971. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group raised their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday. Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $595.75.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $573.07 on Friday. The company has a market capitalization of $216.40 billion, a PE ratio of 33.11, a P/E/G ratio of 3.24 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.50 and a current ratio of 1.50. The company has a 50 day moving average price of $504.04 and a 200-day moving average price of $453.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.